1IA
EGRX

1834 Investment Advisors’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

1834 Investment Advisors’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-42
Closed -$2K – 474
2020
Q2 		$2K Buy
+42
New +$2.1K ﹤0.01% 433

Other funds holding EGRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

1834 Investment Advisors's EGRX Position: Q3 2020 in Review

1834 Investment Advisors sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2020, closing a stake of 42 shares — an estimated $2K sold.

1834 Investment Advisors first reported a position in EGRX in Q2 2020 and held it in 1 quarter. The position peaked at $2K in Q2 2020. 171 funds tracked by Wall St. Rank hold EGRX as of Q3 2020.

  • 1834 Investment Advisors reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
  • 1834 Investment Advisors sold 42 Eagle Pharmaceuticals, Inc. shares in Q3 2020, an estimated $2K.
  • 1834 Investment Advisors first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2020 and held it in 1 quarter.
  • 1834 Investment Advisors's Eagle Pharmaceuticals, Inc. position peaked at $2K in Q2 2020.
  • 171 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2020.

Based on 1834 Investment Advisors's 13F filing for Q3 2020, filed 16 Nov 2020.